Askarpour Mohammadreza, Aminsharifi Alireza
Department of Urology, University of Pittsburgh School of Medicine, Pittsburgh, PA 15232, USA.
Department of Urology, Hershey Medical Center, PennState College of Medicine, Hershey, PA 17033, USA.
Cancers (Basel). 2025 Mar 13;17(6):974. doi: 10.3390/cancers17060974.
: Thermal ablation has emerged as an effective, nephron-sparing treatment for small renal masses (SRMs), particularly in patients with comorbidities. However, tumor recurrence remains a challenge, necessitating evidence-based approaches for salvage management. This review examines the outcomes of minimally invasive modalities for managing recurrence following the primary ablation of SRMs. : A literature review was conducted using the Medline database, following PRISMA guidelines. Studies published between 1981 and 2024 were screened based on predefined PICO criteria. Inclusion focused on patients with tumor recurrence after primary ablation therapy who underwent minimally invasive salvage treatments including repeat ablation, laparoscopic/robotic partial or radical nephrectomy, or active surveillance. Data extracted included patient demographics, initial treatments, recurrence timelines, salvage modalities, and outcomes. : Of 364 patients across 29 studies, 249 (68.4%) underwent re-ablation, 82 (22.5%) were treated with laparoscopic/robotic partial or radical nephrectomy, and 33 (9%) were managed with active surveillance. Among 249 patients with re-ablation, 179 (71.9%) showed no evidence of disease, 67 (26.9%) experienced recurrence, and outcomes were indeterminate in 3 (1.2%). Salvage minimally invasive partial or radical nephrectomy outcomes were available for 64 cases, with 63 (98.4%) showing no recurrence. In 33 patients under active surveillance, 4 died, 4 underwent surgery, and 25 remained under monitoring, though follow-up data were limited. : Minimally invasive salvage modalities, such as re-ablation and laparoscopic/robotic partial or radical nephrectomy, effectively manage tumor recurrence, achieving >70% and >98% oncological success, respectively, despite technical challenges. Future studies directly comparing these modalities are essential for establishing standardized protocols for salvage management.
热消融已成为治疗小肾肿块(SRM)的一种有效的、保留肾单位的治疗方法,尤其是对于合并症患者。然而,肿瘤复发仍然是一个挑战,因此需要基于证据的挽救治疗方法。本综述探讨了SRM初次消融后处理复发的微创治疗方式的疗效。
按照PRISMA指南,使用Medline数据库进行文献综述。根据预先确定的PICO标准筛选1981年至2024年发表的研究。纳入标准聚焦于初次消融治疗后肿瘤复发且接受微创挽救治疗的患者,这些治疗包括重复消融、腹腔镜/机器人辅助部分或根治性肾切除术,或主动监测。提取的数据包括患者人口统计学信息、初始治疗、复发时间线、挽救治疗方式及疗效。
在29项研究的364例患者中,249例(68.4%)接受了再次消融,82例(22.5%)接受了腹腔镜/机器人辅助部分或根治性肾切除术,33例(9%)接受了主动监测。在249例接受再次消融的患者中,179例(71.9%)无疾病证据,67例(26.9%)复发,3例(1.2%)疗效不确定。64例患者有微创挽救性部分或根治性肾切除术的疗效数据,其中63例(98.4%)无复发。在33例接受主动监测的患者中,4例死亡,4例接受了手术,25例仍在监测中,不过随访数据有限。
微创挽救治疗方式,如再次消融和腹腔镜/机器人辅助部分或根治性肾切除术,能有效处理肿瘤复发,尽管存在技术挑战,但肿瘤学成功率分别达到>70%和>98%。未来直接比较这些治疗方式的研究对于制定挽救治疗的标准化方案至关重要。